Form D · Other
Genvax Technologies, Inc.
Ames, IA · CIK 0001940166
Offering snapshot reported Jun 24, 2024 · SEC filing
- Reported sold
- $3.4M Offering amount: $5.25M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 7, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2024 | Initial | $3,399,985 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516694
Series Seed Plus Preferred Stock and the common stock issuable upon conversion thereof.
Source: Form D, filed Jun 24, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joel Harris | Director, Executive |
| Dl Hank Harris | Director |
| Trent Torrance | Director |
Issuer details
Industry: Other (See others in industry)
Address:
2503 S. Loop Drive
Ames, IA, 50010
Ames, IA, 50010